Antimicrobial susceptibility of Streptococcus pyogenes in Central, Eastern, and Baltic European Countries, 2005 to 2006: the cefditoren surveillance program

Integrated Analysis of CANVAS 1 and 2: Phase 3, Multicenter, Randomized, Double‐Blind Studies to Evaluate the Safety and Efficacy of Ceftaroline versus Vancomycin plus Aztreonam in Complicated Skin and Skin‐Structure Infection

“…Although S. pyogenes remains susceptible to most b-lactams, macrolide resistance has increased; recent global estimates range from 6.8% in the United States to 195% in China [14][15][16][17]. In addition, 7.5% of isolates in Belgium were reported to be resistant to fluoroquinolones [18].…”

Synergistic effect of erythromycin on polymorphonuclear cell antibacterial activity against erythromycin-resistant phenotypes of Streptococcus pyogenes

“…Macrolides represent a good alternative in the treatment of S. pyogenes infections in patients who are allergic to penicillin or its derivates [1,2]. Unfortunately, macrolide-resistant S. pyogenes have been isolated in many countries, including Europe and Asia [3][4][5][6]; in Italy the rate of erythromycin resistance in group A streptococci (GAS), which notably increased in the 1990s, is now 25% [7,8].…”

Time–kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes

“…Complicated skin and skin-structure infections (SSSIs) comprise multiple disease states and are most often caused by Staphylococcus aureus and S. pyogenes [1]. Recent studies indicate that there is an increasing trend in the number of erythromycin-resistant isolates causing infections [2,3]. The increased prevalence of drug-resistant isolates underscores the need to identify and develop novel effective antibiotics with which to treat these infections.…”